GreenRoc Strategic Materials Plc (AIM: GROC), is a London listed company focused on the development of critical mineral projects in Greenland, in particular its Amitsoq Graphite Project.
Comments from EU 👇
The partnership package will also support new hydropower plants in Greenland, and the EU is financing preparations for GreenRoc’s Amitsoq graphite project, von der Leyen said.
Huddled Group is currently valued at only around £3m, despite generating £18.65m revenue in FY2025, up 44%.
Now the real catalyst: TikTok Live commerce.
HUD has partnered with a major TikTok agency to push Peeko Beauty through live selling, with further categories planned.
HUD supplies the products and fulfilment.
Their partner supplies the TikTok expertise, studios and presenters.
Profits split 50/50.
If TikTok starts delivering meaningful volume, the numbers could move very quickly.
Here’s the partner from RNS other day
Huddled Group is currently valued at only around £3m, despite generating £18.65m revenue in FY2025, up 44%.
Now the real catalyst: TikTok Live commerce.
HUD has partnered with a major TikTok agency to push Peeko Beauty through live selling, with further categories planned.
HUD supplies the products and fulfilment.
Their partner supplies the TikTok expertise, studios and presenters.
Profits split 50/50.
If TikTok starts delivering meaningful volume, the numbers could move very quickly.
Here’s the partner from RNS other day
Been looking at PAF and the production growth here is pretty hard to ignore. They produced 196,527oz of gold in FY2025 and are now expecting around 275,000oz for FY2026. That’s roughly 40% growth in a year. Mogale is ramping up and they’ve now got the Australian Tennant Mines assets contributing as well. This isn’t an explorer promising production years down the road, they’re already digging it out of the ground and selling it.
The numbers are starting to show what that extra production can do. H1 FY2026 revenue came in at $487.1m, up 157% YoY. Obviously the gold price has given them a massive helping hand, but that’s exactly the point for me. They’ve managed to significantly increase production at a time when gold prices are extremely strong. If they can deliver the ~275koz they’re guiding for, the amount of cash this business can potentially throw off starts getting very interesting. More gold + higher gold prices is a pretty simple investment case.
Block Energy has transformed into a partner-funded growth story, with up to $170m of carried investment across its Georgian projects.
The biggest prize is Project III, containing around 1.4 Tcf net discovered gas. Drilling is expected to begin in H1 2027, with analysts forecasting group production could rise from just 0.5 kboepd to 9.1 kboepd by 2030, while EBITDA climbs from $2.5m to around $65m.
Project IV is also fully carried by Aspect Energy, which is funding 3D seismic and up to three wells targeting the 300m-barrel Martkopi oil prospect.
Then there is Gabon, where BLOE acquired exposure to 75m barrels of discovered resources for a fraction of their estimated value, with a farmout targeted by the end of 2026.
Despite all this, BLOE reportedly trades at less than 10% of total NAV. The broker values the business at 15p per share and has reiterated a 10p target, compared with a current share price below 1p.
Here’s today’s broker note and targets
Block Energy has transformed into a partner-funded growth story, with up to $170m of carried investment across its Georgian projects.
The biggest prize is Project III, containing around 1.4 Tcf net discovered gas. Drilling is expected to begin in H1 2027, with analysts forecasting group production could rise from just 0.5 kboepd to 9.1 kboepd by 2030, while EBITDA climbs from $2.5m to around $65m.
Project IV is also fully carried by Aspect Energy, which is funding 3D seismic and up to three wells targeting the 300m-barrel Martkopi oil prospect.
Then there is Gabon, where BLOE acquired exposure to 75m barrels of discovered resources for a fraction of their estimated value, with a farmout targeted by the end of 2026.
Despite all this, BLOE reportedly trades at less than 10% of total NAV. The broker values the business at 15p per share and has reiterated a 10p target, compared with a current share price below 1p.
Here’s today’s broker note and targets
As per RNS other week (below) new.co.uk is ready for action backed by a £1.3 million marketing campaign, as soon as approval hits Uk. 🇬🇧 Could be a 🦄 this if they get it right. Already got two robotic pharmacies delivering revenue from Nhs and Care Uk prescriptions. Operational break even coming even without ^ this on top.
MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy platform, is pleased to announce the launch of New Health, a dedicated consumer sub-brand focused on the GLP-1 weight-management and broader peptide medicines market opportunity, supported by a £1.3 million national consumer marketing campaign. The launch is being positioned in the context of rapid growth in the GLP-1 category and ahead of the Board's anticipated UK approval of Novo Nordisk's once-daily weight-management pill in summer 2026.
Video Interview with MPAL Ceo
Direct relationship to Novo, one of the most valuable pharmas in the world.
Capacity to expand to respond to demand.
Orders increasing. Feels like right product right time.
https://www.emjreviews.com/emj-gold/news/europe-set-to-get-first-oral-glp-1-weight-loss-pill/
Europe’s medicines watchdog has recommended approval of Novo Nordisk’s semaglutide pill for weight loss, making it the first oral GLP-1 drug backed for use on the continent.
The European Medicines Agency’s (EMA) recommendation on Friday clears the path for the once-daily semaglutide tablet to reach European patients, with full approval expected to follow.
MEDPAL AI (MPAL) has launched New Health, a dedicated consumer sub-brand focused on the fast-growing GLP-1 weight management and broader peptide medicines market, backed by a £1.3 million national marketing campaign. The company said the launch is designed to sharpen its position in the competitive private weight-loss market ahead of a potential UK approval for Novo Nordisk’s oral weight-management pill later this year.
New Health will operate separately from MedPal AI’s broader clinic and consumer platform, acting as a specialist front-end brand while continuing to use the company’s existing regulated healthcare infrastructure, including AI-assisted intake, clinician assessments, pharmacy dispensing and patient monitoring.
The marketing campaign will run over six months, with digital channels expected to be a key focus as MedPal seeks to drive traffic to its new consumer websites and grow recurring patient numbers. Management said performance will be tracked closely across consultation volumes, conversion rates, customer acquisition costs and retention, allowing spend to be adjusted depending on commercial returns and clinical capacity.
Meanwhile, the company pointed to strong sector tailwinds, citing forecasts for rapid growth in UK prescription weight-loss medicines and the possibility that oral GLP-1 treatments could broaden demand by attracting patients reluctant to use injectable therapies. MedPal added that New Health will be supported by its existing NHS-contracted dispensing hubs and supply agreements with Eli Lilly and Novo Nordisk.
MedPal AI’s Founder and Chief Executive Officer Jason Drummond said: “New Health is a focused sub-brand within MedPal AI for a specific opportunity: GLP-1 weight management and the broader peptides category. This market is highly competitive and brand-led, so we need a consumer proposition that can compete on the same terms - a simple brand, a clear message, a dedicated funnel and strong clinical governance behind it.
“MedPal AI remains the operating system for personal health. New Health is the specialist point of access for patients seeking GLP-1 weight-management support and, over time, broader peptide-led healthcare services where clinically appropriate. The patient sees a clear consumer brand; behind it sits MedPal's AI-assisted intake, clinicians, prescribing pathway, pharmacy fulfilment and monitoring.”
MEDPAL AI (MPAL) has launched New Health, a dedicated consumer sub-brand focused on the fast-growing GLP-1 weight management and broader peptide medicines market, backed by a £1.3 million national marketing campaign. The company said the launch is designed to sharpen its position in the competitive private weight-loss market ahead of a potential UK approval for Novo Nordisk’s oral weight-management pill later this year.
New Health will operate separately from MedPal AI’s broader clinic and consumer platform, acting as a specialist front-end brand while continuing to use the company’s existing regulated healthcare infrastructure, including AI-assisted intake, clinician assessments, pharmacy dispensing and patient monitoring.
The marketing campaign will run over six months, with digital channels expected to be a key focus as MedPal seeks to drive traffic to its new consumer websites and grow recurring patient numbers. Management said performance will be tracked closely across consultation volumes, conversion rates, customer acquisition costs and retention, allowing spend to be adjusted depending on commercial returns and clinical capacity.
Meanwhile, the company pointed to strong sector tailwinds, citing forecasts for rapid growth in UK prescription weight-loss medicines and the possibility that oral GLP-1 treatments could broaden demand by attracting patients reluctant to use injectable therapies. MedPal added that New Health will be supported by its existing NHS-contracted dispensing hubs and supply agreements with Eli Lilly and Novo Nordisk.
MedPal AI’s Founder and Chief Executive Officer Jason Drummond said: “New Health is a focused sub-brand within MedPal AI for a specific opportunity: GLP-1 weight management and the broader peptides category. This market is highly competitive and brand-led, so we need a consumer proposition that can compete on the same terms - a simple brand, a clear message, a dedicated funnel and strong clinical governance behind it.
“MedPal AI remains the operating system for personal health. New Health is the specialist point of access for patients seeking GLP-1 weight-management support and, over time, broader peptide-led healthcare services where clinically appropriate. The patient sees a clear consumer brand; behind it sits MedPal's AI-assisted intake, clinicians, prescribing pathway, pharmacy fulfilment and monitoring.”